Biomarin Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.06.21	BioMarin Resubmits MAA To EMA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A (RTTNews)
28.06.21	BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A (PR Newswire)
25.06.21	BioMarin Gets Positive CHMP Opinion For Vosoritide To Treat Achondroplasia (RTTNews)
25.06.21	BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close (PR Newswire)
15.06.21	BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference (PR Newswire)
24.05.21	BioMarin : EMA Grants Accelerated Assessment For Review Of Valoctocogene Roxaparvovec (RTTNews)
19.05.21	BioMarin : Phase 1/2 Study On Hemophilia A Shows Hemostatic Control With Valoctocogene Roxaparvovec (RTTNews)
29.04.21	Biomarin Pharmaceutical Inc. Reports Retreat In Q1 Profit (RTTNews)
28.04.21	Allen Institute, BioMarin To Develop Gene Therapies For Rare Brain Diseases (RTTNews)
25.02.21	Biomarin Pharmaceutical Inc. Bottom Line Rises In Q4 (RTTNews)
11.01.21	Stock Alert: BioMarin Pharma Tumbles 8% (RTTNews)
11.01.21	BioMarin Reports Positive Phase 3 Gene Therapy Trial Results In Adults With Severe Hemophilia A (RTTNews)
21.12.20	BioMarin : Children Treated With Vosoritide Show Cumulative Height Gain At Year 2 (RTTNews)
05.11.20	Biomarin Pharmaceutical Inc. Q3 Earnings Advance (RTTNews)
07.10.20	BioMarin : FDA Okays Maximum Dose Of 60 Mg For Palynziq Injection To Treat Phenylketonuria (RTTNews)
11.09.20	BioMarin To Present Vosoritide Phase 3 Data In Children With Achondroplasia (RTTNews)
08.09.20	BioMarin: Phase 3 Data Show Clinical Benefits Of Vosoritide In Children With Achondroplasia (RTTNews)
20.08.20	JNJ Acquires MNTA, FDA Strikes Down BMRN's Gene Therapy, BLRX's GENESIS On Track, TPTX On Watch (RTTNews)
19.08.20	Stock Alert: BioMarin Plunges 30% After FDA Declines To Approve Its Gene Therapy For Hemophilia A (RTTNews)
13.08.20	BioMarin Pharma: European Medicines Agency To Review MAA For Vosoritide (RTTNews)
04.08.20	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
27.07.20	Biotech Stocks Facing FDA Decision In August 2020 (RTTNews)
17.06.20	BioMarin Issues Additional Data From Valoctocogene Roxaparvovec Study (RTTNews)
04.05.20	BioMarin, DiNAQOR To Develop Gene Therapies For Rare Genetic Cardiomyopathies (RTTNews)
29.04.20	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q1 Earnings Report (RTTNews)
26.02.20	BioMarin Expects To Be Profitable In FY20; Revenue To Rise 14%-20% (RTTNews)
26.02.20	Biomarin Pharmaceutical Inc. Q4 adjusted earnings of -$ per share (RTTNews)
17.12.19	AXSM Again Proves It Is Awesome, MIRM Leaps To $22, WVE Doesn't Go The Distance (RTTNews)
16.12.19	BioMarin: Vosoritide Phase 3 Study Shows Positive Results - Quick Facts (RTTNews)
14.12.19	Are These Biotech Companies Buyout Candidates? Deal Or No Deal? (RTTNews)
23.10.19	Biomarin Pharmaceutical Inc. Q3 adjusted earnings Beat Estimates (RTTNews)
01.08.19	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
28.05.19	BioMarin Reports Positive Data From Valoctocogene Roxaparvovec Study (RTTNews)
25.04.19	Biomarin Pharmaceutical Inc. Q1 adjusted earnings of -$ per share (RTTNews)
01.03.19	BioMarin Pharma: EMA Adopts Positive Opinion On MAA For Palynziq Injection (RTTNews)
21.02.19	Biomarin Pharmaceutical Inc. Q4 adjusted earnings of -$ per share (RTTNews)
10.01.19	10 Gene Therapy Companies Unignorable In 2019 (RTTNews)
28.11.18	Catalysts That Could Move Catalyst Pharma (RTTNews)
26.10.18	Biomarin Pharmaceutical Inc. Q3 adjusted earnings (RTTNews)
02.08.18	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
02.08.18	Biomarin Pharmaceutical Inc. Q2 adjusted earnings of -$ per share (RTTNews)
08.06.18	FDA Nod For EDAP, AGRX Issues Pink Slips, APHB Turns Heads, MNKD Breathes Easy (RTTNews)
07.06.18	BioMarin Receives Milestone Payments from Pfizer for Talazoparib (PR Newswire)
30.05.18	AKER Withdraws 510(K), TTOO Turns Head, CPRX, LOXO To Face FDA In Nov. (RTTNews)
25.05.18	BioMarin Gets FDA Approval For Palynziq Injection To Treat Adults With PKU (RTTNews)
24.05.18	BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease (PR Newswire)
22.05.18	BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018... (PR Newswire)
19.05.18	An Ear To The Pharma: 11 Stocks To Watch (DOVA, SESN, URGN…) (RTTNews)
17.05.18	BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress (PR Newswire)
15.05.18	BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

16.09.24

NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus

16.09.24

NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag

16.09.24

Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer

16.09.24

Verluste in New York: NASDAQ Composite verliert zum Start

06.08.24

Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus

06.08.24

Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich

06.08.24

Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen

06.08.24

Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Biomarin Pharmaceutical Inc.

Aktien Top/Flop

Biomarin Pharmaceutical Peer Group Nachrichten

Meistgelesene Nachrichten